Back to top

BioMarin price target raised to $88 from $82 at Piper Sandler

Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $88 from $82 and keeps an Overweight rating on the shares following quarterly re...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioMarin Pharmaceutical Inc. (BMRN)